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Background: Intensive smoking cessation interventions initiated during hospitalisation are effective, but currently
not widely available. Strategies are needed to integrate smoking cessation treatment into routine inpatient care.
Pharmacist-led interventions for smoking cessation are feasible and efficacious in both ambulatory and community
pharmacy settings. However, there is a lack of evidence from large scale studies of the effectiveness of pharmacist
guided programs initiated during patient hospitalisation in achieving long-term abstinence. This study aims to
evaluate the effectiveness of a pharmacist-led system change intervention initiated during hospitalisation in
Australian public hospitals.
Methods/design: A multi-centre, randomised controlled trial will be conducted with 12 months follow-up.
Smokers, 18 years or older, will be recruited from the wards of three Victorian public hospitals. Participants will be
randomly assigned to a usual care or intervention group using a computer generated randomisation list. The
intervention group will receive at least three smoking cessation support sessions by a trained pharmacist: the first
during the hospital stay, the second on or immediately after discharge and the third within one month post-
discharge. All smoking cessation medications will be provided free of charge during the hospital stay and for at
least one week after discharge. Participants randomised to usual care will receive the current care routinely
provided by the hospital. All measurements at baseline, discharge, one, six and 12 months will be performed by a
blinded Research Assistant. The primary outcome measures are carbon monoxide validated 7-day point prevalence
abstinence at six and 12 months.
Discussion: This is the first large scale study to develop and test a pharmacist-led system change intervention
program initiated during patient hospitalisation. If successful, the program could be considered for wider
implementation across other hospitals.
Trial registration: Australian New Zealand Clinical Trial Registry ACTRN12612000368831.
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Tobacco smoking continues to be the leading cause of
preventable morbidity and mortality worldwide [1].
According to the World Health Organisation, tobacco
use claims almost six million lives every year and, if the
current trend continues, by 2030 tobacco will cause
more than eight million deaths per year worldwide [1].
Smoking contributes to more than 15,500 deaths (11.7%
of total deaths) and 7.8% of the total burden of disease
and injury in Australia [2]. The annual smoking-related
costs to the society are estimated at $31.5 billion [3].
Despite this, one in seven Australians 14 years old and
over continues to smoke every day [4].
Hospitalisation may provide an ideal opportunity for
health professionals to assist people to quit smoking and
it is a potential teachable moment for smoking cessation
[5,6]. At a time of perceived vulnerability to negative
health outcomes, individuals may want to be more aware
about the health risks. They may also be more receptive
to smoking cessation messages and interventions [7,8].
Many Australian hospitals have implemented policies
whereby smoking is not permitted indoors or within
their boundaries outdoors [9]. Health benefits to the
community are likely to be more pronounced if smoking
bans are accompanied by supportive services to assist
smokers to quit [10].
Clinical practice guidelines for treating tobacco use
and dependence recommend that healthcare institu-
tions develop plans to support the consistent and ef-
fective identification, documentation and treatment of
tobacco users [11]. Ginn et al. has described the
initiatives of an interdisciplinary group at an urban aca-
demic medical centre in the United States of America
(USA) in the development and implementation of a to-
bacco cessation protocol [12]. The protocol focused on
admission assessment, education, and provision of
standing orders for medication treatment for nicotine
withdrawal and/or tobacco cessation therapy during the
inpatient encounter and referral for outpatient counsel-
ling on discharge.
High intensity behavioural interventions that are initi-
ated during the hospital stay and include at least one
month of follow-up after discharge have been found to
increase smoking cessation among hospitalised patients
by 37% [13]. Despite the availability of evidence to sup-
port high intensity behavioural interventions and best
practice guidelines on cessation support for hospital in-
patients, low levels of smoking cessation care are pro-
vided [9,14,15]. For example, a survey of patients with a
smoking history admitted to a Victorian tertiary hospital
found that almost half were interested in starting a
smoking cessation program whilst in hospital. Despite
this, only one in five had had any discussion with a
health professional regarding options to assist withquitting in hospital [16]. The barriers to providing effect-
ive smoking cessation include a lack of support from the
organisation, perceived patient objections, a lack of sys-
tems to identify smokers, a lack of time and skill, per-
ceived inability to change care practices, a perceived lack
of efficacy of smoking cessation treatments and the cost
of providing care [17].
Other initiatives are required that include a system
change approach to address the multidimensional prob-
lems associated with smoking care provision [18]. Hav-
ing a dedicated and trained professional for screening,
documenting and providing smoking cessation support
may be an effective approach. Such initiatives are cur-
rently not available in Australia.
Pharmacist-led interventions for smoking cessation
have been shown to be feasible and efficacious in both
hospital outpatient and community pharmacy settings
[19-22]. However, there is no evidence from large scale
studies for the effectiveness of pharmacy interventions
initiated in hospitalised patients that achieve long-term
abstinence. Work has commenced in the USA with the
Consortium of Hospitals Advancing Research on To-
bacco (CHART) network assessing the effectiveness
and cost-effectiveness of a number of projects initiated
during hospitalisation and continued post-discharge.
This project is expected to include 10,000 hospitalised
smokers from 20 hospitals in the USA [10]. However,
this project does not include an intervention with sig-
nificant pharmacy involvement.
We hypothesise that a multi-disciplinary, system
change, high intensity behavioural intervention led by
hospital pharmacists offering pharmacotherapy and non-
pharmacotherapy as needed, that begins during a hos-
pital stay with at least one month of supportive contact
after discharge has the potential to achieve long-term
abstinence.
Objectives
The primary aim of the study is to determine the effect-
iveness of a pharmacist-led system change intervention
(‘GIVE UP FOR GOOD’) compared to usual care on
biochemically verified 7-day point prevalence abstinence
at six months and 12 months.
The secondary objectives are
1. To evaluate the effectiveness of the ‘GIVE UP FOR
GOOD’ intervention compared to usual care on
self-reported continuous abstinence at discharge and
at one, six and 12 months post-discharge.
2. To evaluate the effectiveness of the ‘GIVE UP FOR
GOOD’ intervention compared to usual care on
self-reported 24 hour, 7-day and 30-day point
prevalence abstinence at one, six and 12 months
post-discharge.
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This is a randomised, multi-centre, single blinded study.
Participants will be recruited from the inpatient wards
of three Victorian public hospitals: The Alfred, Austin
Health and Barwon Health. Each participant will be
screened for eligibility at baseline. Eligible participants
will be randomised to either the intervention or usual
care group, and complete four additional follow-up
interviews over a period of 12 months. The ‘GIVE UP
FOR GOOD’ intervention will be delivered over the




















Figure 1 Flow diagram of GIVE UP FOR GOOD study.Inclusion and exclusion criteria
Patients eligible for the trial are 18 years old or older,
are smokers at the time of hospital admission, and are
available for follow-up on discharge, and up to 12
months post-discharge. Exclusion criteria include phys-
ical or mental inability to participate in the study, inabil-
ity to provide written informed consent, inability to
communicate in English, terminal illness, pregnancy or
on another active smoking cessation therapy or program
at the time of hospital admission (pharmacotherapy in-
cluding nicotine replacement therapy (NRT) or active
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from a trained counsellor, health professional or service
provider).Study conduct
Eligible participants will be identified through active
screening of admission, nursing and medical notes by a
Research Assistant (RA) employed at each site. Ward
staff, including doctors, nurses, pharmacists and physio-
therapists will be informed of the research project and
asked to refer all patients identified as current smokers
to the RA. The RA will describe the project to each po-
tential participant, provide a plain language statement
and answer any questions. If he/she is interested in
participating, written informed consent will be sought
before proceeding with the baseline interview. All partic-
ipants will be referred to a study pharmacist for random-
isation after baseline data collection.Randomisation: allocation, concealment and sequence
generation
At each site, patients meeting all the entry criteria will
be randomised by the study pharmacist to either of the
study arms, using a computer generated randomisation
list. Stratified, block randomisation with random block
sizes of four and eight will be used. The study pharma-
cist will be kept unaware of block length to avoid the
predictability of treatment allocation. Participants will be
stratified into two groups using the Heaviness of Smoking
Index (HSI) [23]: heavy smokers (HSI score ≥4) and light
smokers (HSI Score ≤3). Equal proportions of heavy and
light smokers will be approached.
Sealed opaque envelopes will be used for the conceal-
ment of allocation. The study pharmacist will assess the
participants’ nicotine dependence using HSI and cat-
egorise them into the respective stratum. The study
pharmacist will then sequentially select and open an en-
velope corresponding to the stratum to identify treat-
ment allocation and the randomisation number, unique
for each participant.Usual care group
Participants randomised to the usual care (control)
group will continue to receive routine care provided by
the hospital. They may receive brief counselling by hos-
pital staff and/or free NRT or pharmacotherapy during
their hospital stay as per hospital policy. All three par-
ticipating hospitals have a ‘smoke free’ policy; however,
there may be differences between sites in the extent to
which staff offer support to smokers to quit as part of
routine care. The support provided to the usual care
group at each site will be recorded and reported.Intervention group
Participants randomised to the intervention group will
receive the ‘GIVE UP FOR GOOD’ smoking cessation
intervention coordinated by the study pharmacist. The
conceptual framework for the intervention is based on
the systems change approach of Fiore et al. [24], which
has six systems-level strategies to facilitate treatment of
tobacco dependence:
1. Implement a system of identifying smokers;
2. Provide education and resources to promote
provider intervention;
3. Dedicate staff to provide smoking cessation services;
4. Promote hospital policies that support and provide
tobacco dependence services;
5. Include tobacco dependence treatments (both
counselling and pharmacotherapies) identified as
effective; and
6. Reimburse health care providers for delivery of
effective tobacco dependence treatments and include
these services among their defined duties.
In GIVE UP FOR GOOD, trained and dedicated hos-
pital pharmacists take the lead role in providing smoking
cessation support to inpatients at each participating hos-
pital. The pharmacist will record each participant’s smok-
ing status in the medical records and provide cessation
support including counselling and pharmacotherapy.
Intervention procedures
All the intervention pharmacists will complete a two day
smoking cessation training program for health profes-
sionals conducted by the Lung Health Promotion Centre
(LHPC) at The Alfred, Melbourne, Australia. Participants
randomised to the ‘GIVE UP FOR GOOD’ program will
receive a series of smoking cessation counselling sessions
by one of the two specially trained pharmacists at each
hospital over the course of at least three sessions: the first
during the hospital stay, the second on discharge or im-
mediately after discharge and the third within one month
post-discharge. The consistency of intervention across the
sites will be maintained by using standardised treatment
algorithms and procedures, and regular discussions. Phar-
macists will also be regularly attending smoking cessation
update sessions conducted by the LHPC at approximately
six month intervals.
Intervention 1 (after baseline data collection)
Study pharmacists will review the participants’ medical
and medication history in conjunction with their smok-
ing history, nicotine addiction, stages of change, co-
morbidities, quit attempts and outcomes in the past.
The study pharmacist will then discuss with each par-
ticipant the available options for quitting, including
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therapy. Following motivational interviewing, a QUIT
Plan [25] will be prepared for each participant. Resources
such as QUIT Pack®, QUIT Line® and QUIT Coach® and
referral to other staff such as doctors, nurses and dieti-
cians will be used, where appropriate. If prescription med-
ications are required to assist smoking cessation, this will
be discussed with the treating medical staff and provided
free of charge during the hospital stay. Over-the-counter
NRT products may be initiated by the study pharmacists
as required and at the patient’s discretion. Intervention 1
will take approximately 30 minutes.
Intervention 2 (immediately before or after hospital
discharge)
The study pharmacist will reinforce the importance of
quitting, and discuss relapse and relapse prevention
strategies with the participant. A smoking treatment
summary and the discharge plan will be sent to the par-
ticipant’s general practitioner and community pharma-
cist with instructions for post-discharge management
(including non-pharmacological treatment). An appoint-
ment with the primary healthcare professionals will be
made on the participant’s behalf. If participants required
pharmacotherapy for smoking cessation during their
hospital stay, they will receive at least one week’s supply
free of charge at the time of discharge. Intervention 2
will take approximately 15 minutes.
Intervention 3 (within one month after hospital
discharge)
The study pharmacist will follow-up the participant ap-
proximately four weeks post-discharge (by telephone or
mail) to emphasise the importance of long-term abstin-
ence and remind those who have not been reviewed by
their primary health professionals after discharge to seek
ongoing smoking cessation support. Intervention 3 will
take approximately 10 minutes.
Data collection and follow-up
Baseline data collection will be at the time of recruit-
ment. All participants will be followed up for a period of
12 months from hospital discharge. Telephone, mail or
face-face follow-up interviews will be conducted at one,
six and 12 months post-discharge.
General demographics including age, gender, national-
ity, language, education, employment, marital status,
income, living arrangement and possession of any con-
cession card will be collected at baseline. Medical and
medication history will be obtained from the patients’
notes. Smoking-related information including current
smoking status (daily or occasional smoker), age at
which smoking started and smoking habits of friends
and housemates also will be captured. In addition,smoking-related data, such as smoking habits, money
spent on cigarettes, previous smoking cessation attempts
and outcomes, methods used for cessation and difficul-
ties faced during past quit attempts, will be collected.
Preferred methods of cessation, medications, strategies
and facilitators to assist quitting, discussions about smok-
ing cessation with health professionals during the present
hospitalisation and in the past, motivation and confidence
to give up smoking will also be determined. Participant’s
satisfaction with the current services received will be eval-
uated using a five point scale (1- very dissatisfied to
5- very satisfied). Charlson’s Co-morbidity Index [26] will
be used for assessing the co-morbid conditions.
The study will use the following validated scales:
 Heaviness of smoking index (HSI): [23] This is a two
item scale to assess nicotine dependence based on
time to first cigarette of the day and number of
cigarettes smoked per day.
 Patient Health Questionnaire (PHQ-2): [27] This
two item scale will be used to assess the frequency
of depressed mood and inability to experience
pleasure. Each item will be scored on a four point
scale ranging from ‘not at all’ to ‘nearly every day’.
 Smoking self-efficacy scale: [28] Self-efficacy will be
assessed using nine items, in order to determine
temptation to smoke in various situations. Each item
is answered on a five point scale ranging from ‘Not
at all tempted’ to ‘Extremely tempted’ to smoke.
Higher scores indicate greater smoking temptation.
 Readiness to quit ladder: [29] This scale has 10
response options that assess motivation along a
continuum, from ‘not considering quitting in the
near future’ to ‘have already quit smoking’. Higher
scores suggest greater motivation to quit smoking.
 Short Form (SF-8) quality of life questionnaire: [30]
This eight item scale will be used to assess general
health-related quality of life. The scale has domains
on physical and mental health. The items represent
physical functioning, role-physical (role limitations
due to physical health problems), bodily pain,
general health, vitality, social functioning,
role-emotional (role limitations due to personal or
emotional problems) and mental health. A higher
score indicates better health.
 Visual Analogue Scales (VAS) for motivation and
confidence: These scales will be used to assess
participants’ motivation and confidence to give up
smoking on a 10 point scale, with one being ‘very
low’ and 10 being ‘very high’.
The readiness to quit ladder and HSI will be used at
each follow-up. The smoking self efficacy scale and PHQ-
2 will be used at each follow-up, except follow-up 1. The
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end of the study.
Blinding
All assessments will be conducted by a RA blinded to
treatment allocation. All possible measures will be taken
to prevent the revealing of treatment allocation to the
RA. Any accidental unblinding (for example, participant
revealing details of the intervention during a follow-up
interview) will be documented and reported.
Primary endpoint
The primary endpoints are biochemically verified 7-day
point prevalence abstinence at six and 12 months. Par-
ticipants who self-report abstinence of at least seven
consecutive days (7-day point prevalence) at six and 12
months will be asked to perform a carbon monoxide
(CO) breath test. It will be measured using a hand-held
piCO+ Smokerlyzer (Bedfont Scientific, Maidstone, Kent,
England) [31]. Participants will be requested to inhale and
hold their breath for 15 seconds before exhaling into the
analyser. An exhaled CO level of six ppm is recommended
by the manufacturer for distinguishing smokers and non-
smokers. A non-smoker is expected to have a CO level of
0 to 6 ppm, a mildly dependent smoker 7 to 15 ppm and a
strongly addicted smoker over 15 ppm. The instrument
will be calibrated regularly according to the manufac-
turer’s specifications.
Participants who report having smoked more than five
cigarettes in the previous 30 days at the six month
follow-up or in the previous six months at the 12 month
follow-up will be regarded as smokers and will be ex-
cluded from the CO breath test. A participant with a
CO level ≤6 ppm will be considered abstinent. If there is
a conflict between self-reported smoking status and the
CO breath test result, the latter will be taken as the ‘gold
standard’. Participants who fail to complete a follow-up
will be considered to be continuing smokers at that
point.
Secondary endpoints
The secondary outcome measures are 1) Participant self-
reported continuous abstinence (defined as abstinence be-
tween quit day and a follow-up point) at one, six and 12
months. 2) Self-reported 24-hour, 7-day and 30-day point
prevalence abstinence (defined as prevalence of abstinence
during a time window immediately preceding the follow-
up) at one, six and 12 months. 3) Self-reported cigarette
consumption at baseline, one, six and 12 months. 4) Self-
reported spending on cigarettes at baseline, one, six and
12 months. 5) Response to the various validated scales in-
cluding HSI, PHQ-2, smoking self-efficacy scale, readiness
to quit ladder, SF-8 and VAS.Sample size
The abstinence rate at six months was 28% in studies
where trained community pharmacists offered counsel-
ling in conjunction with pharmacotherapy, whereas it
ranged between 8% and 11.8% in the control group
[20,21]. Using a conservative approach based on these
findings, with 250 participants per group, this trial will
have 95% power to detect a 13% difference in the pro-
portion of quitters (25% versus 12%) with a two sided
P-value of 0.05. To allow for a potential drop-out of 20%,
600 patients will be recruited in total. Our aim is to recruit
the required number of participants from three Victorian
hospitals over 12 months, 200 smokers from each hospital
(that is, 100 usual care and 100 intervention).
Statistics and data analysis
Data will be assessed for normality and analysed using
appropriate statistical tests. The baseline demographic
and clinical characteristics will be summarised using
proportions, mean and standard deviation, or median
and interquartile range, as appropriate.
Base-line comparisons: characteristics of study partici-
pants in the intervention and usual care groups will be
compared using the chi-square test for categorical
variables and the Student’s t-test or a non-parametric
equivalent (for example, the Mann–Whitney U test) for
continuous and discrete variables.
Comparisons between the intervention and usual care
group will be performed (both adjusted and unadjusted)
for the known confounders. Analysis of primary out-
come will involve comparing the changes in quit rates
between the two groups. Multivariable analysis will be
used to compare outcomes between the two treatment
groups while adjusting for prognostic variables and po-
tential confounders. Analysis of secondary outcomes will
be conducted using standard statistical procedures ap-
plicable to the categorical, continuous or discrete vari-
ables. All the statistical tests will be interpreted with a
significance level of 5% (two-tailed).
Data will be analysed according to intention-to-treat
(ITT) principles. All randomised participants will be in-
cluded in the analysis and those lost to follow-up will be
regarded as smokers. Participants who die during the
study will be excluded from the analysis [32]. In
addition to ITT analysis, a per protocol analysis also will
be performed.
Ethics
The trial will be conducted in compliance with the
protocol, the principles of Good Clinical Practice (GCP)
[33], the National Health and Medical Research Coun-
cil’s (NHMRC) National Statement on Ethical Conduct
in Human Research (2007) [34] and the Australian Code
for the Responsible Conduct of Research (2007) [35].
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Ethics Committees of all three participating hospitals and
Monash University. Written informed consent will be
obtained from each participant at the time of enrolment.
Discussion
This is the first multi-centre study to develop and evalu-
ate a pharmacist-led system change intervention pro-
gram in hospitalised patients. This is also the first large
scale study to explore the effectiveness of pharmacist in-
terventions in achieving long-term abstinence among in-
patients in Australian hospitals. This project is endorsed
by the Chief Executive Officers and the Directors of
Pharmacy of the participating hospitals which will en-
sure support from hospital staff, thus facilitating the re-
cruitment of participants and conduct of the study. The
three participating hospitals have prohibited smoking in
their premises. Such a smoke free environment will pro-
mote cessation in both usual care and intervention
groups equally. Smoking bans with supportive services
to assist smokers to quit with or without pharmacother-
apy are likely to produce more health benefits to the
community.
Experience from the implementation and evaluation of
the ‘GIVE UP FOR GOOD’ intervention at three sites
will guide the provision of smoking cessation support
for hospital inpatients. If cost effective, the findings of
this study could influence policy changes leading to allo-
cation of more resources to support smoking cessation
initiatives through public hospitals in Australia. If suc-
cessful, the program could be implemented across other
hospitals in Australia and overseas with minimal or no
changes.
Trial status
The trial is currently in the recruitment phase.
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